Pharmacological Treatment In Osteoarthritis (FABIO)
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Hydroxychloroquine
cellulose
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 40 years
- Primary hand OA according to the ACR classification
- Heberden or Bouchard nodule or Kellgren-Lawrence grade 1, 2 or 3 changes in ≥ 2 symptomatic joints
- Pain in the dominant hand ≥ 12 months
- Use of an NSAID for ≥ 1 episode of pain
- Written informed consent
Exclusion Criteria:
- Secondary hand OA, e.g. haemochromatoses, rheumatoid arthritis, posttraumatic
- Kellgren-Lawrence grade 4 OA
- Use of hydroxychloroquine within 3 months before entering the study
- Use of NSAIDs or corticosteroids within 7 days before entering the study
- Retinopathy
- Myasthenia gravis
- Known allergy or hypersensitivity for hydroxychloroquine
Sites / Locations
- Admiraal de Ruyter Hospital
- Maasstad Hospital
- Erasmus Medical Center
- Sint Franciscus Gasthuis
- Vlietland Hospital
- ZorgSaam Zeeuws-Vlaanderen
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Hydroxychloroquine
Arm Description
Outcomes
Primary Outcome Measures
Pain intensity measured by 100 mm Visual Analog Scale (VAS)
Secondary Outcome Measures
Hand function measured by Arthritis Impact Measurement Scales 2 short form (AIMS2-SF) and Australian/Canadian Osteoarthritis Hand Index (AUSCAN)
Pain intensity measured by 100 mm VAS
Radiological progression measured by the anatomical lesion progression system from Verbruggen et al.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01148043
Brief Title
Pharmacological Treatment In Osteoarthritis
Acronym
FABIO
Official Title
Pharmacological Treatment In Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maasstad Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the efficacy of hydroxychloroquine in hand osteoarthritis.
Detailed Description
Osteoarthritis is the most common joint disease, most frequently involving the hands, resulting in pain, stiffness and loss of hand function. At present, there is no option to prevent the onset or the progression of hand osteoarthritis (OA). It is believed that inflammation plays an important role in the pathogenesis of OA and that anti-inflammatory drugs might be an effective treatment for OA. Anti-malarial agents like chloroquine and hydroxychloroquine are potential anti-inflammatory drugs and hydroxychloroquine has already proven to be an effective suppressor of inflammation in rheumatoid arthritis. Several previous studies with hydroxychloroquine in hand OA also showed a possible effect on pain and inflammation, but these studies were mostly retrospective with a small number of patients. This is the first prospective, randomised, placebo-controlled study to determine the effect of hydroxychloroquine in hand osteoarthritis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Hydroxychloroquine
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Hydroxychloroquine
Other Intervention Name(s)
Plaquenil
Intervention Description
200 mg capsule, 2 capsules QD for 24 weeks.
Intervention Type
Drug
Intervention Name(s)
cellulose
Other Intervention Name(s)
placebo
Intervention Description
capsule, 2 capsules QD for 24 weeks
Primary Outcome Measure Information:
Title
Pain intensity measured by 100 mm Visual Analog Scale (VAS)
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Hand function measured by Arthritis Impact Measurement Scales 2 short form (AIMS2-SF) and Australian/Canadian Osteoarthritis Hand Index (AUSCAN)
Time Frame
6, 12 and 24 weeks
Title
Pain intensity measured by 100 mm VAS
Time Frame
6, 12 weeks
Title
Radiological progression measured by the anatomical lesion progression system from Verbruggen et al.
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 40 years
Primary hand OA according to the ACR classification
Heberden or Bouchard nodule or Kellgren-Lawrence grade 1, 2 or 3 changes in ≥ 2 symptomatic joints
Pain in the dominant hand ≥ 12 months
Use of an NSAID for ≥ 1 episode of pain
Written informed consent
Exclusion Criteria:
Secondary hand OA, e.g. haemochromatoses, rheumatoid arthritis, posttraumatic
Kellgren-Lawrence grade 4 OA
Use of hydroxychloroquine within 3 months before entering the study
Use of NSAIDs or corticosteroids within 7 days before entering the study
Retinopathy
Myasthenia gravis
Known allergy or hypersensitivity for hydroxychloroquine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Natalja M Basoski, MD
Organizational Affiliation
Maasstad Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Admiraal de Ruyter Hospital
City
Goes
Country
Netherlands
Facility Name
Maasstad Hospital
City
Rotterdam
ZIP/Postal Code
3079DZ
Country
Netherlands
Facility Name
Erasmus Medical Center
City
Rotterdam
Country
Netherlands
Facility Name
Sint Franciscus Gasthuis
City
Rotterdam
Country
Netherlands
Facility Name
Vlietland Hospital
City
Schiedam
Country
Netherlands
Facility Name
ZorgSaam Zeeuws-Vlaanderen
City
Terneuzen
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
29125901
Citation
Lee W, Ruijgrok L, Boxma-de Klerk B, Kok MR, Kloppenburg M, Gerards A, Huisman M, Hazes M, de Sonnaville P, Grillet B, Weel A, Basoski N. Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2018 Sep;70(9):1320-1325. doi: 10.1002/acr.23471. Epub 2018 Aug 12.
Results Reference
derived
Learn more about this trial
Pharmacological Treatment In Osteoarthritis
We'll reach out to this number within 24 hrs